An approach of automating hippocampal volumetric tool for brain

Alzevita is a cloud-based AI tool developed to assist neuroradiologists and imaging professionals in brain MRI analysis through automated hippocampal segmentation and volumetric reporting. It provides improved consistency, speed, and clinical confidence in quantitative neuroimaging workflows. For model development, a total of 200 MRI brain scans from India were used for training, and 298 MRI scans from the USA were utilized for validation. The tool’s efficiency was evaluated using Dice Score and Hausdorff Distance metrics.

Alzevita enables users to upload brain MRI scans in compatible formats, after which the system automatically segments predefined brain regions using AI, computes precise volumetric measurements, and generates standardized reports for clinical review or research archiving. This facilitates efficient data processing, cross-operator standardization, and scalability across both clinical and research environments.

The platform’s cloud-based processing allows fast computation without dependence on high-end hardware, making it accessible from any device. Alzevita reduces manual workload, enables longitudinal and structural comparisons, and supports future expansion into multi-region brain analysis. By enabling accurate and consistent volumetric analysis, Alzevita supports early diagnosis, disease monitoring, and clinical decision-making in neurological conditions such as Alzheimer’s disease, ultimately empowering clinicians with AI-enhanced precision.

Dibyakanti Mishra is a Scientist and industry professional with deep expertise in neurodegenerative disorders. Her PhD research from Indian Institute of Technology Delhi (IIT Delhi) focused on elucidating the role of optineurin gene mutations in Amyotrophic Lateral Sclerosis (ALS) through cellular studies and whole-exome sequencing of Indian ALS patient DNA, advancing understanding of disease mechanisms and potential therapeutic pathways. Post PhD, she served as a Scientist and Project Investigator at Sun Pharma Advanced Research Company Ltd., where she led and optimized key studies in the neurodegenerative disease domain using advanced biological research methodologies. Currently, She leads techno-commercial initiatives at Topia Lifesciences Ltd. and Topia Medtech Ltd., spearheading the launch of a cutting-edge neurodiagnostic software platform designed for early and precise identification of neurological disorders. Their work bridges scientific research, innovation, and real-world clinical application, with a strong focus on collaborative R&D and translational impact.